U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx Promotion - Proprietary and Established Name Presentation
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.
21 CFR 202.1(b)(1)-(3); 21 CFR 201.10(g); FDA Product Name Placement Guidance (2017)
What is FDA Rx Promotion - Proprietary and Established Name Presentation?
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence. Apply to any prescription drug ad, promotional labeling, web page, video end card or social post that uses the brand name.
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-10-07
What does this rule require?
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.
How can marketing teams comply?
Apply to any prescription drug ad, promotional labeling, web page, video end card or social post that uses the brand name.
What is FDA Rx Promotion - Proprietary and Established Name Presentation?
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
Request a free compliance scan of your homepage and book a time with Warrant.